A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on in-Vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Losmapimod (Primary)
- Indications Atherosclerosis
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 May 2012 EudraCT reports actual initiation date is (1 Apr 2009) and trial status is recruiting.
- 25 Dec 2009 Actual patient number (102) added as reported by ClinicalTrials.gov.
- 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.